

Analyst

Accepted Manuscript



This is an *Accepted Manuscript*, which has been through the Royal Society of Chemistry peer review process and has been accepted for publication.

Accepted Manuscripts are published online shortly after acceptance, before technical editing, formatting and proof reading. Using this free service, authors can make their results available to the community, in citable form, before we publish the edited article. We will replace this *Accepted Manuscript* with the edited and formatted *Advance Article* as soon as it is available.

You can find more information about *Accepted Manuscripts* in the [Information for Authors](#).

Please note that technical editing may introduce minor changes to the text and/or graphics, which may alter content. The journal's standard [Terms & Conditions](#) and the [Ethical guidelines](#) still apply. In no event shall the Royal Society of Chemistry be held responsible for any errors or omissions in this *Accepted Manuscript* or any consequences arising from the use of any information it contains.

Molecular phenotypic profiling of a *Saccharomyces cerevisiae* strain at the single-cell level

Anna M. Schmidt,^{a*} Stephan R. Fagerer,^b Konstantins Jefimovs,^c Florian Buettner,^d Christian Marro,^b
Erdem Siringil,^e Karl Boehlen,^e Martin Pabst,^b and Alfredo J. Ibáñez.^{b,*†}

^aInstitute of Molecular Systems Biology, ETH Zurich, CH-8093 Zurich, Switzerland

^bDepartment of Chemistry and Applied Biosciences, ETH Zurich, CH-8093 Zurich, Switzerland

^cLaboratory for Electronics/Metrology/Reliability, EMPA, Swiss Federal Institute for Material Science and Technology, Überlandstrasse 129, CH-8600 Dübendorf, Switzerland

^dInstitute of Bioinformatics and Systems Biology, Helmholtz-Zentrum München, 85764 Neuherberg, Germany

^eLaboratory for Advanced Materials Processing, EMPA, Swiss Federal Institute for Material Science and Technology, Feuerstrasse 39, CH-3602 Thun, Switzerland

* Contributed equally to this publication

† Corresponding author: Dr. Alfredo Ibáñez; E-mail: alfredo@ethz.ch

ABSTRACT

Studying cell-to-cell heterogeneity requires techniques, which robustly deliver reproducible results with single-cell sensitivity. Through a new fabrication method for the microarray for mass spectrometry (MAMS) platform, we now have attained a robustness and reproducibility in our single-cell level mass spectrometry measurements that allowed us to combine single-cell MAMS-based measurements from different days and samples. By combining multiple measurements, we were able to identify three co-existing phenotypes in an isogenic population of *Saccharomyces cerevisiae* characterized by distinctively different levels of glycolytic intermediates.

INTRODUCTION

Analytical methods capable of studying individual cells play an important role in identifying and characterizing cell-to-cell heterogeneity.¹⁻³ Cell-to-cell (phenotypic) heterogeneity is a natural occurring characteristic that manifests itself in all organisms – including individual cells from an isogenic population – because it ensures an enhanced adaptability to fast changes and/or perturbations in the growth environment.⁴⁻⁷ Several causes can induce cell-to-cell heterogeneity – even stochastic reasons – may lead to different phenotypes of otherwise genetically identical cells. Such cell-to-cell variation has medical relevance, as for example in the case of persistence. Persistence happens when non-genetic cell-to-cell heterogeneity – in an isogenic population – allows a small group of cells to endure the addition of drug to its growth medium (*i.e.*, because they show a better phenotypic adaptation toward the drug).^{6,7} Once the drug is removed, the selection pressure disappears and these surviving cells would give rise to a new (heterogeneous) – but still isogenic – population.^{6,7} It is for this reason that new analytical methods for identifying such cell-to-cell phenotypic variations are greatly required,¹⁻³ in particular when developing a mathematical model of the adaptation and survival mechanisms of a cell population toward a drug.⁴⁻⁷

1
2
3 A novel method for matrix-assisted laser desorption/ionization (MALDI) mass
4 spectrometry (MS), called microarrays for mass spectrometry (MAMS), has been
5 proven to achieve sensitivity for single-cell metabolite detection.⁸⁻¹¹ However, the
6 original method used for the MAMS fabrication (*i.e.*, laser scan ablation) was inefficient
7 in generating microarrays of consistently high quality. Thus, microarray-to-microarray
8 comparison was difficult, since it required numerous normalization steps to
9 compensate the technical noise originated from the microarrays.⁸ Furthermore; such
10 normalization was only possible for certain metabolites. This hampered the ability to
11 pool multiple samples to clearly identify co-existing phenotypes in an isogenic cell
12 population.
13

14
15 Here, we implemented an improved MAMS fabrication process, which should be
16 capable to reduce technical variability. To test the novel MAMS substrates, we
17 analyzed metabolite levels in single cells of the baker' s yeast *Saccharomyces*
18 *cerevisiae*, and for the first time single-cell level measurements from multiple
19 microarrays were combined to generate a total population of 1280 measurements (*i.e.*,
20 an eight-fold increase compared to previous published data).⁸⁻¹¹ As a result of the
21 statistical analysis of the data, three subpopulations with distinctively different levels of
22 glycolytic intermediates were found to co-exist in the isogenic population. Thus, due to
23 the improved MAMS fabrication process, pooling of data from multiple samples is now
24 feasible and therefore now allows using MAMS to confidently identify and characterize
25 co-existing metabolic phenotypes.
26
27
28
29
30

31 EXPERIMENTAL SECTION

32
33 MAMS are fabricated on commercial transparent indium-tin oxide coated cover glass
34 chips (20 mm x 20 mm x 0.16 mm) with a resistivity of 8-12 $\Omega \cdot \text{cm}^{-1}$ (SPI Supplies,
35 Unterfoehring, Germany). The slides were spin-coated (SuSos, Duebendorf,
36 Switzerland) with a 1 μm thick polysilazane coating (CAG 37, marketed by Clariant,
37 Frankfurt am Main, Germany). This polysilazane layer was structured (EMPA, Thun,
38 Switzerland) using projection laser ablation system equipped with an excimer laser
39 (Exitech Ltd., Oxford, UK), with the following characteristics: 20 ns pulse, 248 nm
40 wavelength, 50 Hz repetition rate, and an average fluence at the substrate level was
41 500 mJ/cm^2 per pulse. The laser was collimated to illuminate an area of 16x16 mm^2 on
42 a mask and then focused on the sample with the de-magnification factor of 5 (Figure
43 1A). By scanning the mask under the beam and the sample, a quadratic array of 13 x
44 13 circular recipient sites (100 μm diameter) with a site-to-site distance of 400 μm in
45 both dimensions was created. Recipient sites of larger (1.5 mm in diameter) size were
46 machined outside the 13 x 13 array for depositing metabolite standards to be used as
47 mass calibrants.
48
49

50
51 The *Saccharomyces cerevisiae* mutant strain (*i.e.*, CEN.PK.KOY.TM6*P) was
52 used.^{12,13} This strain exhibits a stochastic cell growth rate, when grown in liquid
53 culture. This observed variability between cultures is present even if the cultures
54 originated from the same colony and were grown under exactly the same growth
55 conditions (similar growth medium, temperature, pH, etc.).
56
57
58
59
60

1
2
3 The cell handling process is as follows, cells were taken from a liquid culture,
4 quenched using a cold (-20°C) methanol:water mixture (3:2 ratio) with ammonium
5 bicarbonate (0.85% w/v, pH 7.4) to stop metabolic activity, after which the supernatant
6 is removed and cells are washed with a methanol:water (3:2 ratio) solution (-20°C) to
7 remove salts. The cell suspension is then aliquoted onto the MAMS substrate (Figure
8 1B). The number of cells is determined by microscopic inspection, while the entire
9 MAMS chip is kept cold (-40°C) in a cryo-chamber flushed with liquid nitrogen.
10 Subsequently, 9-aminoacridine (MALDI matrix) – also cold (-20°C) and in
11 methanol:water (3:2) – is sprayed and the MAMS target is introduced into the MALDI-
12 MS instrument for measurement. Data treatment and analysis was accomplished by
13 transforming the raw data files from the AB5800 instrument to a universal data format
14 (*i.e.*, mzXML) using the freeware program Peak List Conversion Tool, available from
15 <http://www.proteomecommons.org>. Afterwards, the spectral data (*i.e.*, accurate mass,
16 signal intensity, etc.) were calculated using a MATLAB (MathWorks, Natick, MA, USA)
17 peak recognition software that was kindly made available by Uwe Sauer and Nicola
18 Zamboni (Institute of Molecular Systems Biology, ETH Zürich).¹⁴ All spectral data were
19 normalized by a linear combination of unsaturated signals that did not correlate with
20 signals of biological origin. A more detailed description of the cell cultivation, as well as
21 the analysis and data processing can be found in the supplemental information
22 material.
23
24
25

26
27 **Safety considerations:** 9-aminoacridine (9-AA) is a mutagenic substance and it must
28 be handle with care. The selection of 9-AA as a matrix is due to its preferential
29 ionization mechanism,¹⁵⁻¹⁷ which when coupled with the trapping the cells in picoliter-
30 volume reservoirs,⁸⁻¹¹ and the homogenous co-crystallization of matrix and analytes¹⁸
31 is what allows us to reach the "single-cell" level sensitivity.
32
33
34
35

36 RESULTS AND DISCUSSION

37
38 One key step for studying cell-to-cell heterogeneity is to identify the co-existing
39 phenotypes in an isogenic population. Each of these co-existing phenotypes is
40 characterized by a unique metabolic pattern. Unfortunately, when we pool phenotypes,
41 their unique metabolic pattern is diluted due to averaging artifacts (Supplemental
42 Figure 1). In a previous worked, we have observed the natural co-existing
43 subpopulations in an isogenic yeast culture.⁸ However, due to technical limitations
44 (*i.e.*, mostly associated with the limited number of single-cell events), it was not
45 possible to characterize the co-existing populations with enough statistical
46 significance. Here, by using an improved MAMS microarray, this limitation has been
47 overcome.
48
49
50

51 **Single-cell level monitoring of an *S. cerevisiae* isogenic population.**

52
53
54 Variations in the monitored metabolite signal intensity – at the single-cell level – do not
55 necessarily reflect the natural occurring differences in metabolite concentrations, since
56 they can also result from variations in cell size (or other trivial biological artifacts) or
57
58
59
60

1
2
3 instrumental and sample handling variation (analytical artifacts). To illustrate the
4 robustness of our method, as well as its ability to monitor the natural occurring
5 biological variability between the multiple cells within and between set of
6 measurements, we performed a set of control measurements (Supplemental Figure 2-
7 5) described in-detail in the Supplemental section. In summary, these control
8 experiments gave us confidence that the metabolite signal variations were of biological
9 origin and not artifacts influenced by trivial biological variability (cell size), or by the
10 analysis.
11

12
13 After having ensured that we actually monitor biological information, we used our
14 MAMS-based technology to identify the co-existing phenotypes within an isogenic
15 yeast strain population. The *Saccharomyces cerevisiae* (CEN.PK.KOY.TM6*P) strain
16 is an excellent model, because it presents a strong stochastic behavior.¹² This
17 stochasticity is reflected in its ability to grow at different growth rates in liquid culture,
18 even if all cultures were generated from a single colony and were grown under similar
19 conditions. In total, four liquid cultures – each of them with a different growth rate
20 (0.14, 0.16, 0.18, and 0.21 1/h) – were used for this study. Furthermore, the mass
21 spectrometry single-cell data of these 4 liquid cultures were pooled together during a
22 post-data processing step to generate an in-silico “ master” mixed growth-rate cell
23 population (a total of 1280 wells) to obtain a better understanding of the
24 CEN.PK.KOY.TM6*P strain metabolic behavior.
25
26

27
28 The total distribution of the number of cells per reservoir for the whole data set can be
29 seen in Supplemental Table 1. From the 159 wells containing 1 cell per reservoir, only
30 75 were proved suitable for further studies (n=32, 17, 13, and 13 single-cell level
31 measurements for the 0.21, 0.18, 0.16, and 0.14 1/h – cell growth rate samples,
32 respectively). The selection criteria for determining if a single-cell level measurement
33 is good or not was based on the precise mass recognition of 30 central metabolites
34 (Supplemental Table 2) with a maximum mass deviation of 0.02 Da, and an average
35 total mass deviation error of 25 ppm per mass spectra (see Supplemental Information
36 section for additional details).
37

38
39 Interestingly, in Figure 2A, we observed that many cells, independently from the liquid
40 culture they originated from, had similar relative signal intensities of hexose-
41 bisphosphate (very possibly Fructose-1,6-bisphosphate – F16BP).⁸ Therefore, to better
42 study the distribution of abundances of hexose-bisphosphate in the
43 CEN.PK.KOY.TM6*P yeast strain, the histogram for relative signal intensity of hexose-
44 bisphosphate was also plotted, in Figure 2B, for the in-silico “ master” cell population
45 (*i.e.*, the population obtained by pooling all different liquid cultures). Remarkably, the
46 observed distribution of hexose-bisphosphate in Figure 2B is not a symmetric uni-
47 modal Gaussian distribution.^{8,19}
48

49
50 Previously, we have observed that the relative intensity of hexose-bisphosphate can
51 correlate with the cellular levels of F16BP, which presents a bimodal distribution.^{8,19}
52 The validation of the correlation between the cellular levels of F16BP and hexose-
53 bisphosphate was done by performing a tandem MS experiment, as well as a liquid
54 chromatography coupled with mass spectrometry (LC-MS), supplemental figures 4
55 and 5 respectively. Interestingly, by classifying for example all cells in two hypothetical
56 co-existing groups with (i) high and (ii) low levels of F16BP (Figure 2C), a link between
57
58
59
60

1
2
3 higher growth rates and higher levels of F16BP could be made. This was our first hint
4 that the different growth rates could be associated with different ratios of co-existing
5 phenotypes in each liquid culture. In the following section, we aim to describe the
6 differences between these co-existing phenotypes based on their metabolic profiles
7 and not only based on the relative levels of F16BP as done in a previous report.⁸
8
9

10 11 **Identification and characterization at the metabolic level of naturally occurring** 12 **molecular phenotypes in an *S. cerevisiae* isogenic population.** 13

14 Our first goal in this section is the identification of a significant source of cell-to-cell
15 heterogeneity based on the measured mass spectrometry signals. Sources of cell-to-
16 cell heterogeneity can be external and/or internal to the organism. An example of an
17 external factor that contributes to cell-to-cell heterogeneity is that cells can be found in
18 slight different growth environments (*i.e.*, microenvironments) even if grown under
19 exact same conditions. These microenvironments originate due to slight differences in
20 oxygen and nutrient availability, which can impact cellular metabolism.^{20,21} Here, we
21 assume that external source of cell-to-cell heterogeneity, such as oxygen availability,
22 is not predominant since we cannot measured it directly with our system.
23
24

25 For this purpose, we monitor metabolite signals (or metabolite signal ratios) that are
26 used as biomarkers for identifying the cell state. For example, a trivial source of cell-to-
27 cell heterogeneity is cell viability (*i.e.*, cells are either alive or dead).²³ Because the
28 mass spectra signal for adenosine monophosphate could not be identified, the
29 ATP/ADP ratio was used instead of the energy charge for monitoring the viability of the
30 cells.⁸ As it was expected, all single cells measured showed a remarkable constant
31 ATP/ADP ratio, which indicates that all of them were equally viable at the moment of
32 analysis (Figure 3A). This gives additional confidence that our cell handling protocols
33 truly quenched the metabolism of the cells without introducing analytical artifacts.
34
35

36 Another source of cell-to-cell heterogeneity is the cell stage of development. It has
37 recently been demonstrated that the GTP/GDP ratio in combination with cytosolic pH
38 act as a triggering signal for yeast growth by activating the Ras/TOR signal cascade.²⁴
39 Since we did not attempt to synchronize our yeast cultures prior collecting the
40 samples, it is not surprising to see a greater amount of variability (biological noise)
41 between the individual cells (Figure 3B), in particular when compared to the previous
42 parameter (cell viability).
43
44

45 Finally, another source of cell-to-cell heterogeneity is associated with how cells
46 process the available nutrients in the growth medium (*i.e.*, glucose). Therefore, a ratio
47 that could be easily linked to the way fermentation is performed was plotted. One of
48 the metabolites that we chose for this ratio was F16BP, whose levels in yeast cells
49 have been correlated with carbon uptake via the anaerobic glycolysis pathway.^{25, 26}
50 The other metabolites was phosphoenolpyruvate (PEP), which strongly correlates with
51 the pentose phosphate pathway activity.²⁷ Interestingly, when compared the ATP/ADP
52 and the GTP/GDP ratio data dispersion, which have a clear uni-modal distribution; the
53 plot of the F16BP/PEP ratio (Figure 3C) presents a bimodal distribution. It is important
54 to state that this bimodal distribution is not associated to the previously observed
55 bimodal distribution observed for F16BP (this will be better clarified in the following
56 paragraphs). It is also an interesting observation that the overall dispersion (coefficient
57
58
59
60

1
2
3 of variability, CV) for this ratio is higher than the one observed for ATP/ADP (Figure
4 3A), while at the same time lower than the one observed for the GTP/GDP (Figure
5 3B). This is interesting because the natural occurring cell-to-cell heterogeneity
6 reflected by the F16BP/PEP ratio fluctuates between two conserve values, even when
7 the overall biological noise (reflected by the GTP/GDP ratio) is much higher. Since
8 these finding shows that glycolysis has a role in the cell-to-cell heterogeneity observed
9 for this yeast strain, we will attempt first to classify the cells based only on their
10 F16BP/PEP cellular ratio. Once this classification has taken place, we will compare
11 our results with a non-supervise classification. Based on our measurements, we
12 tentatively assigned three different phenotypes, labeled here as: (i) Group 1, (ii) Group
13 2, and (iii) Group 3 (Figure 4A). Due to the ability of mass spectrometry to
14 simultaneously monitor multiple metabolite signals from the central metabolism, we
15 can describe each group in terms of a metabolic pattern (Figure 4B).
16
17

18
19 We will now compared the above result with the one obtained from a non-bias
20 classification based on the whole metabolic profile of the cells. For this purpose, the 75
21 single-cell mass spectra was analyzed using a non-supervise principal component
22 analysis (MatLab, MathWorks). To have confidence that the analysis represents
23 biological information, we identified the principal component that fulfills the following
24 conditions: (i) it could explain most of the population variance; and (ii) its loading
25 values for the signals of F16BP and PEP will have opposite signs (*i.e.*, they will be
26 anti-correlated as it is to be expected).²⁷ In our case, both conditions were fulfilled by
27 the Principal Component 4. In Supplemental Figure 6, we plot the principal
28 components 1 vs 4. Each point corresponds to a single yeast cell, and is described by
29 332 relative ion intensity signals (normalized by a single correction factor, as described
30 in the Supplemental information section). On the one hand, due to 97.8% of all the
31 loading values for the PC1 (33.6% of the sample variance) were positive, we
32 hypothesize that the PC1 represent a trivial biological trait/feature (*i.e.*, size) or an
33 analytical artifact, *e.g.*, laser fluctuations that – although minimized by our analytical
34 protocol – cannot be completely removed from the analysis. On the other hand, we
35 hypothesize that the Principal Component 4 (7.9% of the sample variance) is
36 associated with the natural occurring cell-to-cell heterogeneity because (i) the loadings
37 associated with the Principal Component 4 show different signs, in particular for
38 metabolites from competing metabolic pathways such as PEP and F16BP and (ii)
39 known metabolite MS signals (Supplemental Table 2) scored – either positive or
40 negative – high loading values. Interestingly, the level of non-trivial (metabolite) cell-to-
41 cell variability (*i.e.*, the variance contribution of PC4) found here is realistic and in
42 agreement with models of metabolic cell-to-cell heterogeneity that assumes variations
43 between 5 and 10% for glycolytic intermediates.¹⁹ The groups obtained in the principal
44 component analysis confirm to some extend our previous classification based
45 exclusively on the F16BP/PEP signal ratio. Group 1 is clearly isolated from Group 2
46 and 3, due to its characteristic metabolic profile (as described in Figure 4B), while
47 Group 2 and 3 share a more common metabolic profile. Although, a supervised PCA
48 approach, in which only the mass spectrometry signals of selected metabolites, could
49 have improved the clustering of the cells in groups 2 & 3, it would not have yielded a
50 significant improvement over the classification based on the F16BP/PEP signal ratio.
51
52
53
54

55 Following the tentative identification of the molecular phenotypes, we plotted the
56 distribution of these molecular phenotypes in terms of its relative levels of F16BP – in
57 an analogous way to the one shown in Figure 2 (Figure 5A), considering 100% to be
58
59
60

1
2
3 the “master” population (*i.e.*, all measured cells). Interestingly, by reducing the
4 technical and analytical variability, we could de-convolute the overlapping populations
5 with low F16BP levels (based on the above introduced classification, Figure 4).
6 Furthermore, we can clearly observe that only Group 3 (*i.e.*, with high levels of
7 glycolytic activity) presents the before mentioned F16BP bi-stability – the presence of
8 both high and low level F16BP populations. In Figure 5B and 5C, we demonstrate that
9 the different growth rates observed for this yeast strain can now be clearly correlated
10 with an increasing number of yeast cells with high glycolytic activity, and in more detail
11 with those yeast cells that showed high levels of F16BP. This result – the correlation
12 between glycolysis and cell growth – is in accordance with the Warburg effect, which
13 states the increased utilization of glucose via glycolysis as a cellular resource for fast
14 cell growth.²⁶
15
16

17
18 Finally, in Supplemental figure 7, we can take advantage of the analytical power
19 associated with the pooling of single-cell level measurements and compare the mass
20 spectra of one particular cell vs another cell (Supplemental figure 7A), or for example
21 between the pooled mass spectra of two different phenotypes (Supplemental figure
22 7B) and perform an in-depth statistical analysis to find the key-differences between the
23 two populations. For example, when compared with our first attempt to characterize
24 the high and low F16BP populations using our single-cell platform,⁸ the possibility of
25 accumulating larger numbers of single-cell data, with a lower technical/analytical
26 variability, allowed us to perform a 2-sample t-test statistical study on both populations.
27 Furthermore before performing this comparison, we can remove from the high and low
28 F16BP populations (characterized by a high glycolysis activity) other cells that might
29 present similar levels of F16BP but present different levels of glycolytic activity. Thus,
30 in addition to the trivial difference in F16BP, the High and Low F16BP populations can
31 be differentiated for example in terms of adenosine triphosphate, uracil triphosphate,
32 and 3-deoxy-D-arabino-heptulosonic-acid-7-phosphate (p values equal 6×10^{-5} ,
33 2.69×10^{-3} , and 1.89×10^{-3} , respectively).
34
35

36
37 Furthermore, we can now also observe that metabolite-metabolite correlations present
38 unique information about the metabolic networks' underlying system architecture for
39 each phenotype. In Figure 6A, the “average” partial rank correlation for those
40 metabolites that have been described in supplemental table 2. While, figure 6B, 6C,
41 and 6D, the partial rank correlation for a selected cluster of metabolites belonging to
42 Group 1, Group 3b, and Group 3a are shown. Interestingly, cells associated with
43 Group 1 (low glycolytic activity) the partial correlation between oxaloacetate and
44 coenzyme A is quite strong. However, the correlation between these two metabolites
45 becomes fainter for the cells from Group 3 (high glycolytic activity). In addition, cells
46 from group 3 shows the additional correlation between these two metabolites and
47 phosphogluconolactone. The latter correlation even differs in the case if the cell levels
48 F16BP are high or low (Group 3a and 3b, respectively). It would be tempting at this
49 stage to provide a metabolic model that explains the differences between the observed
50 phenotypes (in particular for Group 1, Group 3a and Group 3b). However, a more in-
51 depth analysis is required prior developing such biological model. Fortunately, the
52 MAMS substrates are compatible with fluorescence microscopy measurements, thus it
53 would be possible to label transcription factors and/or proteins with fluorescent protein
54 tags to monitor the up- or down-regulation of a particular metabolic pathway. For this
55 reason, we believe that a MAMS-based mass spectrometric analysis at the single-cell
56
57
58
59
60

1
2
3 level is a great first step in trying to understand the causes for cell-to-cell
4 heterogeneity.
5

6
7 In summary, this new generation of microarrays for mass spectrometry is able to show
8 the non-genetic heterogeneity present in a clonal population, and it might prove useful
9 as a first line of study to better understand cell-to-cell heterogeneity. The possibility of
10 coupling these transparent substrates with a fluorescent read-out could be the next
11 step to better identify the biological processes that allows the formation of different
12 non-genetic phenotypes to appear. This could be of great interest in a clinical research
13 application, where a clonal population of cells might present non-genetic heterogeneity
14 (e.g., cancer cells). A MAMS-based approach could identify different phenotypes, and
15 possibly identify the effect of a drug on these populations in such way that after
16 measuring the cell population at different time points we could identify the surviving
17 phenotype. This would then really lead to a “tailor-made” therapy for diseases, such as
18 cancer.
19

20 21 22 23 CONCLUSIONS

24
25 In this study we exploit a new microfabrication method (*i.e.*, projection laser ablation)
26 for the fabrication of microarrays for mass spectrometry. By using this new generation
27 of MAMS substrates, we reduced the technical (or analytical) variability to be able to
28 directly visualize four different co-existing phenotypes (characterized by the cellular
29 levels of glycolytic intermediates) in an isogenic cell population of *Saccharomyces*
30 *cerevisiae* strain, CEN.PK.KOY.TM6*P. The existence of these subpopulations in
31 different ratios can be correlated to the different growth rates observed in the liquid
32 cultures of this particular yeast strain.
33
34

35
36 There is in theory no limitation to the number of single-cell level measurements that
37 can be performed and combined to compare/characterize – with statistical significance
38 – individual cells, a group of cells that are phenotypically similar, or the whole cell
39 population (the latter two by pooling selected or all the individual results together,
40 respectively). Because, we exploit the inherent variability between individual cells (e.g.
41 due to cell cycle, stochastic effects, cell age, cell size, etc.) as a potent system
42 perturbation, we could observe differences in the metabolic networks' underlying
43 system architecture. This information in combination with the ability of this platform to
44 calculate the biological variance, and the number of co-existing phenotypes, can be
45 later used for data driven modeling or for designing more complex biological
46 experiments to validate the existence of the co-existing phenotypes.
47
48

49 50 CONFLICT OF INTERESTS

51 S.R.F., K.J., and M.P. are developing a commercial product based on the microarray
52 for mass spectrometry technology.
53
54

55 56 ACKNOWLEDGEMENTS

57 A.J.I. gratefully acknowledges the financial support of the Ambizione Program of the
58 Swiss National Science Foundation (SNF) (PZ00P3_142615), and the support of the
59
60

1
2
3 following ETH Zürich professors: Prof. Dr. Renato Zenobi (who hosts the research of
4 A.J.I.), Prof. Dr. Petra Dittrich, Prof. Uwe Sauer, and Prof. Dr. Matthias Peter, who
5 granted access to their facilities to perform the experiments. S.R.F., K.J., and M.P.
6 were supported by the Swiss KTI (Kommission für Technologie und Innovation) Grant
7 No. 13123.1 PFNMNM. The authors also would like to thank: (i) Karin Elbing for
8 providing the CEN.PK.KOY.TM6*P yeast strain, (ii) the support of AB Sciex, in
9 particular Tobias Schibli, who granted free access to the AB5800 MALDI TOF/TOF
10 instrument, (iii) Fabian Wahl, Gerd Hayenga, Jens Boertz and Rudolf Köhling from
11 Sigma-Aldrich, Switzerland for their support during the microarray chip development;
12 and (iv) Prof. Dr. Matthias Heinemann, Dr. Reinhard Dechant, Dr. Madina Mansurova,
13 and Robert Steinhoff for their advice, support and thoughtful insights during the
14 drafting of this publication.
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

References:

1. R. Zenobi, *Science*, 2013, **342**, 6163.
2. A. Svatos, *Anal. Chem.*, 2011, **83**, 5037-5044.
3. M. Heinemann, R. Zenobi, *Curr. Opin. Biotechnol.*, 2011, **22**,26-31.
4. S.J. Altschuler, L.F. Wu, *Cell*, 2010, **141**,559-563.
5. A. Raj, A. van Oudenaarden *Cell*, 2008, **35**,216-226.
6. S.V. Avery, *Nat. Rev. Microbiol.*, 2006, **4**(8), 577-587.
7. N.Q. Balaban, J. Merrin, R. Chait, L. Kowalik, S. Leibler, *Science*, 2004, **305**, 1622-1625.
8. A.J. Ibáñez, S.R. Fagerer, A.M. Schmidt, P.L. Urban, K. Jefimovs, P. Geiger, R. Dechant, M. Heinemann, R. Zenobi, *Proc Natl Acad Sci U S A.*, 2013, **110**(22), 8790-8794.
9. S.R. Fagerer, T. Schmid, A.J. Ibáñez, M. Pabst, R. Steinhoff, K. Jefimovs, P.L. Urban, R. Zenobi, *Analyst*, 2013, **138**, 6732-6736.
10. P.L. Urban, A.M. Schmidt, S.R. Fagerer, A. Amantonico, A. Ibañez, K. Jefimovs, M. Heinemann, R. Zenobi, *Mol Biosyst.*, 2011, **7**(10), 2837-2840.
11. P.L. Urban, K. Jefimovs, A. Amantonico, S.R. Fagerer, T. Schmid, S. Mädler, J. Puigmarti-Luis, N. Goedecke, R. Zenobi, *Lab Chip.*, 2010, **10**(23), 3206-3209.
12. A.M. Schmidt, PhD thesis, ETH Zürich, 2013.
13. K. Elbing, C. Larsson, R.M. Bill, E. Albers, J.L. Snoep, E. Boles, S. Hohmann, L. Gustafsson, *Appl. Environ. Microbiol.*, 2004, **70**, 5323-4330.
14. T. Fuhrer, D. Heer, B. Begemann, N. Zamboni, *Anal. Chem.*, 2011, **83**(18), 7074-7080.
15. D. Yukihiro, D. Miura, Y. Fujimura, Y. Umemura, S. Yamaguchi, S. Funatsu, M. Yamazaki, T. Ohta, H. Inoue, M. Shindo, H. Wariishi, *J. Am. Soc. Mass. Spectrom.* 2014, **25**(1), 1-5.
16. S.R. Fagerer, S. Nielsen, A. Ibáñez, R. Zenobi, *Eur. J. Mass Spectrom.*, 2013, **19**, 39-47.
17. R.L. Vermillion-Salsbury, D.M. Hercules, *Rapid Commun. Mass Spectrom.* 2002, **16**,1575-1581.
18. M. Pabst, S.R. Fagerer, R. Köhling, S.K. Küster, R. Steinhoff, M. Badertscher, F. Wahl, P.S. Dittrich, K. Jefimovs, R. Zenobi, *Anal. Chem.*, 2013, **85**(20), 9771-9776.
19. J.H. van Heerden, M.T. Wortel, F.J. Bruggeman, J.J. Heijnen, Y.J. Bollen, R. Planqué, J. Hulshof, T.G. O'Toole, S.A. Wahl, B. Teusink, *Science*, 2014, **343**(6174), 987.
20. D.A. Elias, S.L. Tollaksen, D.W. Kennedy, H.M. Mottaz, C.S. Giometti, J.S. McLean, E.A. Hill, G.E. Pinchuk, M.S. Lipton, J.K. Fredrickson, Y.A. Gorby, *Arch. Microbiol.*, 2008, **189**(4), 313-324.
21. M.R. Mashego, K. Rumbold, M. De Mey, E. Vandamme, W. Soetaert, J.J. Heijnen, *Biotechnol. Lett.* 2007, **29**(1), 1-16.
22. S. Christen, U. Sauer, *FEMS Yeast Res.*, 2011, **11**(3), 263-272.
23. A. Amantonico, P.L. Urban, S.R. Fagerer, R.M. Balabin, R. Zenobi, *Anal. Chem.*, 2010, **82**, 7394-7400.
24. R. Dechant, S. Saad, A. Ibáñez, M. Peter, *Mol. Cell*, 2014, **55**, 1-13.
25. D.H. Huberts, B. Niebel, M. Heinemann, *FEMS Yeast Res.*, 2012, **12**(2),118-128.
26. H. Pelicano, D.S. Martin, R.H. Xu, P. Huang, *Oncogene*, 2006, **25**, 4633-4646
27. N.M. Grüning, M. Rinnerthaler, K. Bluemlein, M. Mülleder, M.M. Wamelink, H.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Lehrach, C. Jakobs, M. Breitenbach, M. Raiser, *Cell Metab.*, 2011, **14(3)**, 415-427.

Analyst Accepted Manuscript

FIGURE CAPTIONS

Figure 1. Graphical summary of the workflow used to prepare the samples for single-cell MALDI MS analysis. Cellular metabolism is quenched by adding a cold (-20°C) solution of 3:2 Methanol:Water with 0.85%(v/v) ammonium bicarbonate (pH 7.4). After cell handling (*i.e.* centrifugation and discarding the supernatant), the pellet is reconstituted in a salt free cold (-20°C) solution of 3:2 Methanol:Water, and the cell suspension is spread onto a cold MAMS chip. Applying the cell suspension onto the MAMS surface will result in an automated aliquoting of the cell suspension into the hydrophilic reservoirs, without the need for a microspotter. Dependent on the cell concentration employed, the number of cells on each hydrophilic reservoir can be between zero and hundreds (random Poisson distribution). The transparency of the MAMS substrate allows for microscopic analysis to determine the number of cells in each reservoir while the cells remain quenched because the entire MAMS chip is kept cold in a cryo-chamber using liquid nitrogen. After counting the cells under the microscope, 9-aminoacridine (MALDI matrix) is applied with an airbrush, and each reservoir on the plate is analyzed with MALDI MS.

Figure 2. (A) The MAMS-based analytical protocol is able to avoid biological and technical artifacts due to averaging of a large number of cells by performing a single-cell level analysis on the liquid medium grown cells. Therefore, we observed that within a “theoretical” homogeneous clonal population of cells, there is enough cell-to-cell heterogeneity to form different phenotypes which may contribute to the observed differences in growth rate. (B) By pooling all the cell samples together, we can observe that there is a correlation between increasing levels of F16BP and the growth rate of the cell population (C). The identification of fructose-1,6-bisphosphate (F16BP) is based on precise mass, and tandem MS experiment (supplemental figure 4), which was performed on standard stainless steel target with a higher density of yeast cells (~1000 cells). The fragmentation spectrum of hexose-bisphosphate was then compared to a commercially available sample of F16BP. Furthermore, LC-MS measurements were performed. On the LC-MS measurements, the levels of F16BP in different mutants of the CEN.PK.KOY yeast strain (each of them presenting a different growth rate) had a positive correlation; a trend that was also obtained from the different liquid cultures of the CEN.PK.KOY.TM6 strain using our MAMS platform (supplemental figure 5). With this experiment, we have not only confirmed that the hexose-bisphosphate signal is F16BP, but also that the level of F16BP signal in the sample correlates with the observed cell growth as shown in Figure 2.



Figure 3. The ratios of ATP/ADP, GTP/GDP, and F16BP/PEP were plotted to compare the different levels of biological noise associated with the cell-to-cell heterogeneity. For example, difference in viability is a source of cell-to-cell heterogeneity. The energy charge was not used because for our MS measurements the adenosine monophosphate (AMP) signal did not fulfill our signal selection criteria (explained in the supplemental information). Instead the ratio between ATP/ADP was used to estimate the cell viability (see text for details). Here, we can observe that viability is not a strong source of cell-to-cell heterogeneity. While, the ability of the cells to sense their carbon source (*i.e.*, glucose) in the different cultures is. The ratio of GTP/GDP is a triggering signal for cell growth, and in combination with cytosolic pH is directly link to the sensing of glucose in the cell environment. The high coefficient of variability for the GTP/GDP ratio shows that this can be one of the major sources of cell-to-cell heterogeneity. However, even in a quite noisy system (as illustrated by the GTP/GDP ratio), the distribution of the F16BP:PEP ratio falls between two conserved values. Thus, we hypothesized that the different co-existing phenotypes could be characterized in terms of their associated glucose degradation. CV is the abbreviation for coefficient of variation.




Figure 4. (A) The Log(F16BP/PEP) is plot in decreasing order. A binomial distribution can be observed, were two groups, Group 1 and Group 3, are clearly differentiated by the levels of glycolytic activity (Group 1 with low and Group 3 with high levels of anaerobic glycolytic activity, respectively). In between these two groups, few cells can be found. These cells are part of Group 2, which is an intermediate state between Groups 1 and 3. (B) Based on these three groups, a decision tree can be constructed. Using a t-test statistical approach, key metabolites that are statistical different can be retrieved. For example, for the first decision step – used to differentiate Group 1 from the rest – guanosine triphosphate and phospho-gluconolactone can be used as part of the selection criteria (p-values are 7.83×10^{-8} , 8.11×10^{-6} respectively). For the second decision step, aspartate and phosphoenol pyruvate (p-values are 5.89×10^{-5} and 2.09×10^{-3} , respectively) can be used.

Figure 5. Three (3) core groups (or phenotypes) could be identified over the previous once shown in


1
2
3 Figure 2B, based on the mass spectrometry signals of the central metabolism (as shown in Figure 4).
4 (A) The histogram of fructose-1,6-bisphosphate for all measured yeast samples (*i.e.*, pooled data –
5 shown in Figure 2B) is further de-convoluted using these three groups that are characterized by different
6 levels of glycolytic activity. By de-convoluting the co-existing populations, it is possible to avoid
7 overlapping of three different phenotypes that present similar levels of F16BP, but show different
8 glycolysis activity (100% = 75 cells, which is the total population of measured yeast cells). (B) The co-
9 existence of these three groups in different ratios is also associated with the growth rates observed in
10 liquid growth medium (100% = 32, 17, 13, and 13, for the 0.21, 0.18, 0.16, and 0.14 1/h – cell growth
11 rate samples, respectively). (C) The Group 3 (*i.e.*, the group characterized by a high glycolytic activity)
12 can be further subdivided in two sub-populations, one with high and another with low levels of fructose-
13 1,6-bisphosphate (100% as in Figure 5B). Figures 5B & 5C show that it is the relative abundance of
14 these four subgroups in the overall population (and not only 2 based on a high and low F16BP
15 phenotypes) what can explain the growth rates observed for the CEN.PK.KOY.TM6*P populations.

16 **Figure 6.** (A) Partial rank correlation for the whole population of measured cells based on the post-
17 measurement pooling of the mass spectra from Groups 1, 2, 3a & 3b characterized by low glycolytic,
18 intermediate, high glycolytic activity (with high and low levels of fructose-1,6-bisphosphate),
19 respectively. (B) Partial rank correlation for a small subset of metabolites using the data obtained
20 exclusively from Group 1 (*i.e.* low glycolytic activity yeast cells). (C) Partial rank correlation for a small
21 subset of metabolites using the data obtained exclusively from Group 3b (high glycolytic activity with low
22 cellular levels of F16BP yeast cells). (D) Partial rank correlation for a small subset of metabolites using
23 the data obtained exclusively from Group 3a (high glycolytic activity with high cellular levels of F16BP
24 yeast cells).
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

A**Analyst****B**




1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




■ F16BP ● Log(GTP/GDP)
◇ Log(ATP/ADP) □ Log(F16BP/PEP)




1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

A




B





A

Groups 1+2 + 3a+3b




Blue: negative correlation
 Red: positive correlation
 False discovery rate: 0.01

Analyst Accepted Manuscript


B

Group 1
 (Low glycolytic activity)




C

Group 3b
 (High glycolytic activity + low levels of F16BP)



D

Group 3a
 (High glycolytic activity + high levels of F16BP)



1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47